Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC25A21 (Mitochondrial 2-oxodicarboxylate carrier) is a transporter protein located on the inner mitochondrial membrane that mediates the exchange of C5-C7 oxodicarboxylates, notably importing 2-oxoadipate and exporting 2-oxoglutarate[1][2][3][5]. It plays a critical role in the catabolism of lysine, hydroxylysine, and tryptophan, importing 2-oxoadipate—a key intermediate—into the mitochondria where it is converted to acetyl-CoA and funneled into the citric acid cycle[1][2][3]. Pathogenic variants can cause mitochondrial DNA depletion syndrome 18 and neuromuscular disease by disrupting amino acid breakdown and mitochondrial energy metabolism[3][1]. SLC25A21 is also being investigated as a prognostic marker in cancers such as acute myeloid leukemia, reflecting its broader importance in mitochondrial function and apoptosis regulation[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial 2-oxodicarboxylate carrier (SLC25A21).